OpGen Reports First Quarter 2023 Financial Results and Provides Business Update
Total revenue for the first quarter of 2023 was approximately $0.91 million, an increase of…
News
OpGen Reports First Quarter 2023 Financial Results and Provides Business Update
Total revenue for the first quarter of 2023 was approximately $0.91 million, an increase of…
Sanara MedTech Inc. Announces First Quarter 2023 Results
FORT WORTH, TX, May 15, 2023 (GLOBE NEWSWIRE) — Sanara MedTech Inc. Based in Fort…
Sanara MedTech Inc. Announces First Quarter 2023 Results
FORT WORTH, TX, May 15, 2023 (GLOBE NEWSWIRE) — Sanara MedTech Inc. Based in Fort…
Timber Pharmaceuticals Provides Business Update and Announces First Quarter 2023 Financial Results
– Timber has now Enrolled Over 60% of Patients for Pivotal TMB-001 Phase 3 ASCEND…
Timber Pharmaceuticals Provides Business Update and Announces First Quarter 2023 Financial Results
– Timber has now Enrolled Over 60% of Patients for Pivotal TMB-001 Phase 3 ASCEND…
PaxMedica, Inc. Provides First Quarter 2023 Business Update; Phase 3 HAT-301 Top Line Results Expected in Second Half 2023
TARRYTOWN, NY, May 15, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD),…
PaxMedica, Inc. Provides First Quarter 2023 Business Update; Phase 3 HAT-301 Top Line Results Expected in Second Half 2023
TARRYTOWN, NY, May 15, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD),…
Molecular Templates, Inc. Reports First Quarter 2023 Financial Results and Business Update
Advancing clinical development of MT-6402, MT-8421, and MT-0169, and preclinical activities related to Bristol Myers…
Molecular Templates, Inc. Reports First Quarter 2023 Financial Results and Business Update
Advancing clinical development of MT-6402, MT-8421, and MT-0169, and preclinical activities related to Bristol Myers…
Reviva Reports First Quarter 2023 Financial Results and Recent Business Highlights
– Topline data for pivotal Phase 3 RECOVER trial for brilaroxazine in schizophrenia expected mid-2023…
Reviva Reports First Quarter 2023 Financial Results and Recent Business Highlights
– Topline data for pivotal Phase 3 RECOVER trial for brilaroxazine in schizophrenia expected mid-2023…
Aprea Therapeutics Reports First Quarter 2023 Financial Results and Provides Update on Business Operations
DOYLESTOWN, Pa., May 15, 2023 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the…
Aprea Therapeutics Reports First Quarter 2023 Financial Results and Provides Update on Business Operations
DOYLESTOWN, Pa., May 15, 2023 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the…
Ardelyx, Inc. Reports Employment Inducement Grants
WALTHAM, Mass., May 15, 2023 (GLOBE NEWSWIRE) — Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company…
Ardelyx, Inc. Reports Employment Inducement Grants
WALTHAM, Mass., May 15, 2023 (GLOBE NEWSWIRE) — Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company…
NightHawk Biosciences Provides Q1 2023 Business Update
DURHAM, N.C., May 15, 2023 (GLOBE NEWSWIRE) — NightHawk Biosciences (NYSE American: NHWK), a fully…
NightHawk Biosciences Provides Q1 2023 Business Update
DURHAM, N.C., May 15, 2023 (GLOBE NEWSWIRE) — NightHawk Biosciences (NYSE American: NHWK), a fully…
Biora Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
Completed execution of toxicology study for NaviCap™ BT-600 program with no adverse events indicated in…
Biora Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
Completed execution of toxicology study for NaviCap™ BT-600 program with no adverse events indicated in…